Key result
Intramuscular injection of AAV2/9 expressing CT domain-extended microdystrophin (MD2) significantly improved muscle resistance to lengthening contraction-induced muscle damage in mdx mice compared with MD1.
Why the study?
Does AAV2/9 expressing CT domain-extended microdystrophin (MD2) improve muscle pathology and restore α1-syntrophin and α-dystrobrevin levels in mdx mice compared to MD1?
Does AAV2/9 expressing CT domain-extended microdystrophin (MD2) improve muscle pathology and restore α1-syntrophin and α-dystrobrevin levels in mdx mice compared to MD1?
p-value: p=<0.001
Incorporation of helix 1 of the coiled-coil motif in the CT domain of dystrophin to microdystrophins improves their efficiency in restoring muscle function and protecting against contraction-induced damage in a mouse model of Duchenne muscular dystrophy.
May support microdystrophin optimization in DMD models; leaves open human translation and clinical testing.
Duchenne muscular dystrophy is a severe X-linked inherited muscle wasting disorder caused by mutations in the dystrophin gene. Adeno-associated virus (AAV) vectors have been extensively used to deliver genes efficiently for dystrophin expression in skeletal muscles. To overcome limited packaging capacity of AAV vectors (<5 kb), truncated recombinant microdystrophin genes with deletions of most of rod and carboxyl-terminal (CT) domains of dystrophin have been developed. We have previously shown the efficiency of mRNA sequence–optimized microdystrophin (ΔR4-23/ΔCT, called MD1) with deletion of spectrin-like repeat domain 4 to 23 and CT domain in ameliorating the pathology of dystrophic mdx mice. However, the CT domain of dystrophin is thought to recruit part of the dystrophin-associated protein complex, which acts as a mediator of signaling between extracellular matrix and cytoskeleton in muscle fibers. In this study, we extended the ΔR4-23/ΔCT microdystrophin by incorporating helix 1 of the coiled-coil motif in the CT domain of dystrophin (MD2), which contains the α1-syntrophin and α-dystrobrevin binding sites. Intramuscular injection of AAV2/9 expressing CT domain–extended microdystrophin showed efficient dystrophin expression in tibialis anterior muscles of mdx mice. The presence of the CT domain of dystrophin in MD2 increased the recruitment of α1-syntrophin and α-dystrobrevin at the sarcolemma and significantly improved the muscle resistance to lengthening contraction–induced muscle damage in the mdx mice compared with MD1. These results suggest that the incorporation of helix 1 of the coiled-coil motif in the CT domain of dystrophin to the microdystrophins will substantially improve their efficiency in restoring muscle function in patients with Duchenne muscular dystrophy. In this study, Koo and colleagues demonstrated that intramuscular delivery of AAV2/9 expressing a microdystrophin with helix 1 of the coiled-coil motif in the C-terminal domain increases the recruitment of α1-syntrophin and α-dystrobrevin at the sarcolemma of skeletal muscle fibers in a mouse model of Duchenne muscular dystrophy, and efficiently protects from lengthening contraction-induced muscle damage.
No takes yet. Share an insight, caveat, or question.
Koo et al. (2011) studied Duchenne muscular dystrophy (mdx mouse model). AAV2/9-microdystrophin incorporating helix 1 of the coiled-coil motif in the CT domain (MD2) vs. AAV2/9-MD1 (lacking CT domain) or saline was evaluated on Maximal force deficit following a series of six lengthening (eccentric) contractions (p=<0.001). Intramuscular injection of AAV2/9 expressing CT domain-extended microdystrophin (MD2) significantly improved muscle resistance to lengthening contraction-induced muscle damage in mdx mice compared with MD1.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: